We wish to inform that the Board approved the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended on 31.03.2026
SHIVALIK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.6 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shivalik Rasayan Ltd reported audited results for FY26. Standalone revenue grew 13% to Rs 17,120 Lakhs from Rs 15,129 Lakhs, while consolidated revenue rose 16% to Rs 37,208 Lakhs from Rs 32,008 Lakhs, driven by Pharma Formulations segment showing strong growth. However, standalone net profit declined 41% to Rs 817 Lakhs (EPS Rs 5.19 vs Rs 8.80), and consolidated PAT fell 12% to Rs 1,797 Lakhs despite higher revenues, indicating margin compression due to increased raw material costs and employee expenses. The board recommended a 10% dividend (50 paise per share). Key changes include resignation of Non-Executive Director Mr. Sanjay Bansal, appointment of new Internal Auditor M/s Arun Agarwal & Co (replacing M/s Amar Sharma & Co), and appointment of Cheena & Associates as Cost Auditor. Statutory auditors gave an unmodified (clean) opinion.
Revenue growth shows business expansion but sharp profit decline raises concerns about cost control and margin sustainability. The director resignation and committee reconstitution may indicate governance changes. Clean audit provides confidence in financial reporting accuracy.